Clinical trial: Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Status: TERMINATED
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma
Interventions: DRUG: Abemaciclib|DRUG: Abiraterone|DRUG: Afatinib|BIOLOGICAL: Bevacizumab|DRUG: Bicalutamide|PROCEDURE: Biospecimen Collection|DRUG: Bortezomib|DRUG: Cabazitaxel|DRUG: Cabozantinib|DRUG: Capecitabine|DRUG: Carboplatin|DRUG: Celecoxib|DRUG: Cobimetinib|DRUG: Copanlisib|DRUG: Dabrafenib|DRUG: Dacomitinib|DRUG: Darolutamide|DRUG: Dasatinib|DRUG: Doxorubicin|BIOLOGICAL: Durvalumab|DRUG: Enasidenib|DRUG: Entrectinib|DRUG: Enzalutamide|DRUG: Erlotinib|DRUG: Everolimus|DRUG: Fluorouracil|DRUG: Idelalisib|DRUG: Imatinib|BIOLOGICAL: Ipilimumab|DRUG: Lenvatinib|DRUG: Leucovorin|DRUG: Lorlatinib|DRUG: Losartan|DRUG: Nab-paclitaxel|DRUG: Neratinib|BIOLOGICAL: Nivolumab|DRUG: Olaparib|DRUG: Oxaliplatin|DRUG: Palbociclib|DRUG: Panobinostat|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Pertuzumab|DRUG: Ponatinib|OTHER: Quality-of-Life Assessment|DRUG: Regorafenib|DRUG: Ruxolitinib|DRUG: Sirolimus|DRUG: Sorafenib|DRUG: Sunitinib|DRUG: Trametinib|BIOLOGICAL: Trastuzumab Emtansine|DRUG: Tretinoin|DRUG: Vemurafenib|DRUG: Venetoclax|DRUG: Vismodegib|DRUG: Vorinostat
Study Type: INTERVENTIONAL
Study Design: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT